Abstract:Background: Current hypertension guidelines recommend combination of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker with a calcium-channel blocker or thiazide diuretic as initial antihypertensive therapy in patients with monotherapy uncontrolled hypertension. However, to what extent these two different combinations are comparable in blood pressure (BP)-lowering efficacy and safety remains under investigation, especially in the Chinese population. We investigated the BP-lowering efficacy and safety of the amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies in Chinese patients. Methods: In a multi-center, randomized, actively controlled, parallel-group trial, we enrolled patients with stage 1 or 2 hypertension from July 2018 to June 2021 in 20 hospitals and community health centers across China. Of the 894 screened patients, 560 eligible patients were randomly assigned to amlodipine/benazepril 5/10 mg (n = 282) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 278), with 213 and 212 patients, respectively, who completed the study and had a valid repeat ambulatory BP recording during follow-up and were included in the efficacy analysis. The primary outcome was the change from baseline to 24 weeks of treatment in 24-h ambulatory systolic BP. Adverse events including symptoms and clinically significant changes in physical examinations and laboratory findings were recorded for safety analysis. Results: In the efficacy analysis (n = 425), the primary outcome, 24-h ambulatory systolic BP reduction, was - 13.8 ± 1.2 mmHg in the amlodipine/benazepril group and - 12.3 ± 1.2 mmHg in the benazepril/hydrochlorothiazide group, with a between-group difference of - 1.51 (p = 0.36) mmHg. The between-group differences for major secondary outcomes were - 1.47 (p = 0.18) in 24-h diastolic BP, - 2.86 (p = 0.13) and - 2.74 (p = 0.03) in daytime systolic and diastolic BP, and - 0.45 (p = 0.82) and - 0.93 (p = 0.44) in nighttime systolic and diastolic BP. In the safety analysis (n = 560), the incidence rate of dry cough was significantly lower in the amlodipine/benazepril group than in the benazepril/hydrochlorothiazide group (5.3% vs 10.1%, p = 0.04). Conclusions: The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering. The former combination, compared with the latter, had a greater BP-lowering effect in the daytime and a lower incidence rate of dry cough. Trial registration: ClinicalTrials.gov, NCT03682692. Registered on 18 September 2018.

Randomized, double-blind, parallel controlled,multicentre clinical trial of fixed combination of nitrendipine and atenolol in the treatment of mild to moderate essential hypertension

Efficacy and Safety of Fixed Combination of Nitrendipine and Atenolol in Treatment for Patients with Mild to Moderate Essential Hypertension and Their Optimal Dosage Matching

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

The Combination of Perindopril and Indapamide in Treatment of Essential Hypertension

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients with Stable Angina Pectoris in China

Effects of Atenolol and Diltiazem-Sr on Quality of Life in the Hypertensive Patients

Nitrendipine and Enalapril Combination Therapy in Mild to Moderate Hypertension: Assessment of Dose-Response Relationship by a Clinical Trial of Factorial Design

A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients.

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment

Combination Of Amlodipine With Diuretics Or Telmisartan In High-Risk Hypertensive Patients: The Chinese Hypertension Intervention Efficacy Study (Chief)

A clinical trial for evaluating efficacy and safety of amlodipine besylate/atorvastatin calcium in treating hypertension complicated with hyperlipidemia

Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China.

Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats.

Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial

Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 Mg or Perindopril Tert-Butylamine 4 Mg Monotherapy

The Efficacy and Safety of the Compound Felodipine Sustained-Release Tablets in Mild to Moderate Essential Hypertension: a Double-Blind Randomized Clinical Trials

[Efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in the acute treatment of moderate and severe hypertension: a randomized, double-blind, positive-drug parallel-controlled, multi-center clinical study]

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial

Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension